Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 14/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1504630 | 0.90 | KDM4E (0.52) | KDM4EMEN1POLBMAPTMAPK1 | |
| SCHEMBL10042723 | 0.89 | KDM4E (0.52) | KDM4EMEN1POLBMAPTMAPK1 | |
| SCHEMBL1504706 | 0.87 | MAPK14 (0.48) | KDM4EMEN1POLBMAPTMAPK1 | |
| SCHEMBL1504506 | 0.85 | MAPK14 (0.56) | KDM4EMEN1POLBMAPTMAPK1 | |
| SCHEMBL1504173 | 0.85 | MAPK14 (0.55) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL1504459 | 0.83 | MAPK14 (0.54) | KDM4EMEN1POLBMAPTMAPK1 | |
| SCHEMBL1504402 | 0.81 | KMT2A (0.42) | KDM4EMEN1POLBMAPTMAPK1 | |
| SCHEMBL1504773 | 0.80 | MAPK14 (0.55) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL1504734 | 0.79 | MAPK14 (0.53) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL1504522 | 0.79 | MAPK14 (0.49) | KDM4EMEN1POLBMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173684-B2 | Pyridone derivatives as p38α MAPK inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-05-08 | — | — | US | disclosed |
| EP-2155683-B1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | MAPK1, MAPK6, MAPK3 | KDM4E 1656/4885MEN1 4446/4885POLB 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.